Health
Designer DNA therapies shown to effectively target cancer stem cells – The Science Board
Using an engineered DNA therapeutic agent to silence transcription factor genes reduced myeloma stem cell abundance and increased the survival of mice bearing human…
Multiple myeloma is the second most common blood cancer in the U.S. It generally recurs and is refractory (reoccurs and is unresponsive to treatments). Despite novel therapies, treatment toxicities continue to be a challenge for patients and clinicians.
In multiple myeloma, proinflammatory cytokines and antiviral interferons derived from bone marrow play a key role in disease progression, including activation of interleukin 6 (IL-6) with downstream interferon-response factor (IRF) signaling.
IRF4…
-
Noosa News23 hours agoQueensland government and nurses and midwives reach in-principle pay deal after months of negotiation
-
Noosa News12 hours agoPill checking to resume in Queensland months after government axed funding
-
Noosa News22 hours agoBrisbane nation’s third-youngest capital; Leaders condemn anti-immigration rally
-
Business15 hours agoWhy Austal, Boss Energy, Harvey Norman, and NextDC shares are charging higher today